Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
Abstract Lenvatinib is one the most active drugs in radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) such that it has become an important therapeutic tool in tumor control and survival. Renal and hepatic impairments are common comorbidities in cancer patients. Treating these patients is...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wiley
2022-10-01
|
| Sarja: | Cancer Medicine |
| Aiheet: | |
| Linkit: | https://doi.org/10.1002/cam4.5130 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|